Filing Details

Accession Number:
0000874015-22-000140
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-07-19 19:20:58
Reporting Period:
2022-07-15
Accepted Time:
2022-07-19 19:20:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874015 Ionis Pharmaceuticals Inc IONS Pharmaceutical Preparations (2834) 330336973
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1206369 Iii Joseph Klein 2855 Gazelle Court
Carlsbad CA 92010
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-07-15 5,333 $0.00 17,459 No 4 M Direct
Common Stock Acquisiton 2022-07-15 2,665 $0.00 20,124 No 4 M Direct
Common Stock Disposition 2022-07-15 689 $37.74 19,435 No 4 S Direct
Common Stock Disposition 2022-07-15 644 $38.78 18,791 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit Disposition 2022-07-15 5,333 $0.00 5,333 $0.00
Common Stock Restricted Stock Unit Disposition 2022-07-15 2,665 $0.00 2,665 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
9,775 No 4 M Direct
7,110 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 100 Indirect by Son
Common Stock 6,000 Indirect by Trust
Footnotes
  1. Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
  2. Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.
  3. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 18, 2020.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.26 to $38.225 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.44 to $39.23 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) on this Form 4.
  6. The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  7. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
  8. Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.
  9. Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.